The First of Its Kind in the World: The Recombinant Multivalent COVID-19 Protein Vaccine against XBB Variants by WestVac Biopharma/West China Medical Center, Sichuan University has been Approved for Clinical Trials by The National Medical Products Adminis
PR NewswireMay 19, 2023
CHENGDU, China, May 18, 2023 /PRNewswire/ -- On May 17, 2023, Recombinant bivalent COVID-19 protein vaccine (Sf9 cells) and recombinant trivalent COVID-19 trimeric protein vaccine (Sf9 cells) developed by WestVac Biopharma/ West China Medical Center, Sichuan University against the most recent circulating XBB variants, received the "Drug Clinical Trial Approval" from the National Medical Products Administration of China. These two new vaccines will be quickly commercialized for protecti